The Globe and Mail reports in its Friday, Sept. 27, edition that in reaction to Kits Eyecare's inaugural Investor Day event on Tuesday, Canaccord Genuity analyst Luke Hannan increased his share target to $14.50 from $12.50 with an unchanged "buy" ranking. The Globe's David Leeder writes that analysts on average target the shares at $14.36. Mr. Hannan says in a note: "In our view, Kits Eyecare remains well positioned to maintain its current growth trajectory, driven by its state-of-the-art manufacturing operations, product innovation and focus on high-return customer acquisition channels such as influencer marketing. A deeper dive on each of the above topics throughout the day led us to come away with greater conviction that the company can achieve its internal goal of generating $500-million of annual revenue in five years' time, implying a revenue CAGR [compound annual growth rate] of 25 to 30 per cent, realizing ample margin expansion through operating leverage over that period as well." The Globe reported on July 24 that Ventum Capital rated Kits "buy." It was then worth $9.80. The Globe reported on Aug. 22 that Haywood Securities analyst Gianluca Tucci rated Kits "buy." The shares could then be had for $10.68.